UpDoc Wins First FDA Clearance for Patient-Facing LLM App
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- UpDoc announced in late June that its diabetes app received FDA clearance for medical software using 'patient-facing large language models,' with the clearance actually granted in December.
- UpDoc, founded in 2023, plans to deploy the technology as part of a care model helping health systems manage patients outside the clinic through AI.
- The cleared device is an app in which patients input data via voice and text and receive treatment instructions, regulated in the same product category as drug dose calculators that take blood glucose readings and return insulin dosing recommendations.
- The app's LLM interface communicates results back to a doctor's electronic medical record software to keep physicians in the loop on patient interactions.
- The milestone triggered industry discussion over whether the LLM functions as an interface relaying doctor-set treatment plans or as something closer to a decision-maker shaping patient care.
Why it matters: The clearance — described as the first for patient-facing LLM medical software — places UpDoc in a new regulatory lane shared with drug dose calculators, setting a precedent for how the FDA reviews apps where an LLM sits between a physician's plan and a patient's daily dosing decisions.
